385 Oyster Point #9A
South San Francisco
119 articles with Vaxart, Inc.
Vaxart Hosting Key Opinion Leader Meeting on the Health Economics of Norovirus DiseaseNorovirus represents a $3+billion U.S. market opportunity
Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that it will host a key opinion leader (KOL) meeting on the health economics of norovirus disease on Thursday, November 14th in New York City.
Vaxart, Inc. Announces Changes to its Board of DirectorsThe company has appointed four new members to the Board of Directors
Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that four new members have been appointed to the Board of Directors effective immediately.
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Wouter Latour, M.D., president and chief executive officer of Vaxart, will present a company update and overview at the H.C. Wainwright 21st Annual Global Investment Conference on Tuesday, September 10, 2019, at 12:30 p.m. EST in New York.
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced financial results for the second quarter ended June 30, 2019.
Oral Universal Flu Vaccine Candidate to be Evaluated in Pre-Clinical Challenge Model
Vaxart, Inc. announced that Roberto Mateo, Ph.D., senior scientist at Vaxart, will present preclinical results of its oral Respiratory Syncytial Virus vaccine in a poster presentation at the American Society of Microbiology 2019, taking place from June 20-24, 2019 in San Francisco, California.
Vaxart, Inc. announced the publication of the comprehensive results from a preclinical trial of its chikungunya vaccine in the peer reviewed journal, Vaccine.
Vaxart Doses First Patient in Randomized Cohort of Bivalent Norovirus Vaccine Phase 1b Clinical Trial
Vaxart, Inc. announced it has started dosing subjects in the randomized cohort of the Phase 1b bivalent norovirus vaccine clinical trial.
100% Survival Against Lethal H5N1 Avian Flu Challenge in Ferret Study
Vaxart, Inc. announced the pricing of an underwritten public offering of 9,090,010 shares of common stock, and common warrants to purchase up to an aggregate of 9,090,010 shares of common stock.
Vaxart, Inc. announced participation in two upcoming global medical meetings in April.
Vaxart, Inc. announced the completion of dosing of the lead-in cohort in the Phase 1b bivalent norovirus vaccine clinical trial with its oral norovirus GII.4 vaccine.
When it comes to biotech and pharma innovation few places stand out like the Biotech Bay. The area is home to a plethora of innovative companies that are shaping the future of medical treatment for a variety of diseases and conditions on a daily basis.
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the closing of its previously announced registered direct offering of 1,200,000 shares of its common stock at a price of $2.50 per share
First Dosing with Norovirus GII.4 Oral Tablet Vaccine Scheduled for Week of March 18
Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale in a registered direct offering priced at-the-market of 1,200,000 shares of the Vaxart’s common stock,
Initiation of Two Norovirus Vaccine Trials Expected in 1H 2019
Vaxart, Inc. today announced that Sean Tucker, Ph.D., chief scientific officer, will present summary data from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine at the World Vaccine and Immunotherapy Congress West Coast 2018, taking place from November 28-30, 2018 in San Diego, California.
10/15/2018Who mixed things up in the biotech world this past week? Pfizer announces its leadership team, Rheos gets a new COO, and board of directors updates from multiple biopharma companies.
New Data from Phase 2 Flu Challenge Study Demonstrates Vaxart’s Oral H1 Flu Vaccine Generated Protective Mucosal Immunity
Vaxart oral tablet vaccine provided 39% reduction in flu illness compared to 27% for Fluzone®